Skip to content

Prospective Evaluation of Anorganic Bovine Bone Mineral Versus Calcium Phosphosilicate Alloplastic Bone Putty in Direct Sinus Augmentation: a Spilt-mouth Study

Prospective Evaluation of Anorganic Bovine Bone Mineral Versus Calcium Phosphosilicate Alloplastic Bone Putty in Direct Sinus Augmentation: a Spilt-mouth Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01942304
Enrollment
12
Registered
2013-09-13
Start date
2013-10-01
Completion date
2019-05-31
Last updated
2019-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maxillary Sinus, Sinus Floor Augmentation

Keywords

Sinus Floor Augmentation, Maxillary Sinus, Bone Substitutes, Bone Regeneration

Brief summary

The purpose of this split-mouth clinical study is to evaluate the clinical, radiographic and histological outcomes of lateral window sinus augmentation with a bovine xenograft or a CPS putty bone substitute in posterior maxillary sites and the survival of implants placed in these sites following healing.

Interventions

PROCEDURECalcium phosphosilicate alloplastic bone putty in direct sinus augmentation
PROCEDUREAnorganic bovine bone mineral in direct sinus augmentation

Sponsors

NovaBone Products, LLC
CollaboratorINDUSTRY
University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients with non-contributory medical history that will present for bilateral sinus lift surgery prior to implant placement

Exclusion criteria

* Patients that will not agree to participate in this study or sign the consent form * More than 8mm of residual bone height at the implant site * Subjects smoking more than 10 cigarettes per day * History of acute sinus infection * History of prior maxillary sinus surgery (Caldwell-Luc, direct or indirect sinus lift, etc) * Medications that affect bone healing (chronic steroid regimen, oral or IV bisphosphonates, etc.) * Patients allergic to bovine derivatives * Patients who are a carrier of transmissible disease(s) that may unnecessarily expose laboratory personnel to risks * Females during pregnancy or lactation or females that plan to become pregnant in the following year (pregnancy test prior to enrollment)

Design outcomes

Primary

MeasureTime frameDescription
Percentage of new bone growth in the maxillary sinus7 months(plus minus 1 month)Difference between the percentage of new bone growth between the two groups as determined by histomorphometric analysis of bone cores retrieved during implant placement surgery.

Secondary

MeasureTime frameDescription
Gain in vertical bone height6 months (plus or minus 1month)Patients will be seen for radiographic evaluation post-sinus surgery. A cone beam computed tomography (CBCT) will be obtained and a blinded investigator will evaluate the vertical bone height at the sites.
Radiographic bone density6 months (plus or minus 1 month)Patients will be seen for radiographic evaluation. A cone beam computed tomography(CBCT) will be obtained and a blinded investigator will evaluate the volumetric grey values at each site as an index of bone quality.
Primary implant stability7 months (plus or minus 1 month)Primary stability of implants placed in the augmented sinuses will be evaluated as a clinical index of bone density.
Marginal bone level maintenance12 months(plus or minus 1 month)Intraoral radiographs, using a paralleling technique, with customized film holders will be obtained at baseline (time of abutment connection) and at the 12-month follow-up visit and evaluated by an independent investigator to assess marginal bone levels around the implant platform. The measurements will be performed mesially and distally of each implant.

Other

MeasureTime frameDescription
Implant success2nd stage, 6&12 months post-loadingPatients will be evaluated for clinical symptoms and implant success using predetermined criteria.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026